| Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals A Grifoni, D Weiskopf, SI Ramirez, J Mateus, JM Dan, CR Moderbacher, ... Cell 181 (7), 1489-1501. e15, 2020 | 3980 | 2020 |
| Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection JM Dan, J Mateus, Y Kato, KM Hastie, ED Yu, CE Faliti, A Grifoni, ... Science 371 (6529), eabf4063, 2021 | 2910 | 2021 |
| Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 Q Zhang, P Bastard, Z Liu, J Le Pen, M Moncada-Velez, J Chen, M Ogishi, ... Science 370 (6515), eabd4570, 2020 | 2169 | 2020 |
| SARS-CoV-2 vaccines in development F Krammer Nature 586 (7830), 516-527, 2020 | 2158 | 2020 |
| A serological assay to detect SARS-CoV-2 seroconversion in humans F Amanat, D Stadlbauer, S Strohmeier, THO Nguyen, V Chromikova, ... Nature medicine 26 (7), 1033-1036, 2020 | 2026 | 2020 |
| Immunology of COVID-19: current state of the science N Vabret, GJ Britton, C Gruber, S Hegde, J Kim, M Kuksin, R Levantovsky, ... Immunity 52 (6), 910-941, 2020 | 1719 | 2020 |
| SARS-CoV-2 vaccines: status report F Amanat, F Krammer Immunity 52 (4), 583-589, 2020 | 1432 | 2020 |
| Robust neutralizing antibodies to SARS-CoV-2 infection persist for months A Wajnberg, F Amanat, A Firpo, DR Altman, MJ Bailey, M Mansour, ... Science 370 (6521), 1227-1230, 2020 | 1232 | 2020 |
| Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development M Imai, K Iwatsuki-Horimoto, M Hatta, S Loeber, PJ Halfmann, ... Proceedings of the National Academy of Sciences 117 (28), 16587-16595, 2020 | 1004 | 2020 |
| Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine F Krammer, K Srivastava, H Alshammary, AA Amoako, MH Awawda, ... New England Journal of Medicine 384 (14), 1372-1374, 2021 | 810 | 2021 |
| SARS‐CoV‐2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup D Stadlbauer, F Amanat, V Chromikova, K Jiang, S Strohmeier, ... Current protocols in microbiology 57 (1), e100, 2020 | 755 | 2020 |
| SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses JS Turner, JA O’Halloran, E Kalaidina, W Kim, AJ Schmitz, JQ Zhou, T Lei, ... Nature 596 (7870), 109-113, 2021 | 682 | 2021 |
| Advances in the development of influenza virus vaccines F Krammer, P Palese Nature reviews Drug discovery 14 (3), 167-182, 2015 | 652 | 2015 |
| The human antibody response to influenza A virus infection and vaccination F Krammer Nature Reviews Immunology 19 (6), 383-397, 2019 | 607 | 2019 |
| Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity SV Bardina, P Bunduc, S Tripathi, J Duehr, JJ Frere, JA Brown, ... Science 356 (6334), 175-180, 2017 | 571 | 2017 |
| Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C) CN Gruber, RS Patel, R Trachtman, L Lepow, F Amanat, F Krammer, ... Cell 183 (4), 982-995. e14, 2020 | 560 | 2020 |
| Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study STH Liu, HM Lin, I Baine, A Wajnberg, JP Gumprecht, F Rahman, ... Nature medicine 26 (11), 1708-1713, 2020 | 531 | 2020 |
| The first 12 months of COVID-19: a timeline of immunological insights T Carvalho, F Krammer, A Iwasaki Nature Reviews Immunology 21 (4), 245-256, 2021 | 471 | 2021 |
| Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies F Krammer, N Pica, R Hai, I Margine, P Palese Journal of virology 87 (12), 6542-6550, 2013 | 458 | 2013 |
| Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses N Pardi, MJ Hogan, MS Naradikian, K Parkhouse, DW Cain, L Jones, ... Journal of Experimental Medicine 215 (6), 1571-1588, 2018 | 455 | 2018 |
Natalie PicaIcahn school of medicine at mount sinai在 mssm.edu 的电子邮件经过验证
Natalie PicaIcahn school of medicine at mount sinai在 mssm.edu 的电子邮件经过验证